KRAS and pancreatic neoplasm: The cell line carries both KRAS and TP53 gene mutations, which are ubiquitous driver-gene mutations in pancreatic cancer, and are responsible for the expression of tumor biomarkers, carcinoembryonic antigens, and carbohydrate antigens 19–9 (32, 33).